Gland Pharma Q3 net up 7% at ₹205 crore
Gland Pharma’s consolidated net profit increased 7 per cent at ₹205 crore in the third quarter ended December 2024 compared to ₹192 crore in the corresponding quarter of previous financial year.
The total revenue of the Hyderabad based company, however, declined 10 per cent at ₹1384 crore in the quarter under review compared to ₹1,545 crore in the same period last year. The lower expenses offset the impact of production issues at its French unit Cenexi on the net but impacted the revenue.
“Our Q3 FY25 revenue was at ₹13,841 million with an EBITDA of ₹3,600 million , resulting in a 26 per cent EBITDA margin. Notably, our base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39 per cent,’‘ Srinivas Sadu, Executive Chairman, Gland Pharma said in a release.
“We are also excited about the progress of our strategic biologies CDMO collaborations with some of the leading companies in this space. These partnerships open doors to exciting opportunities in the rapidly growing biologies CDMO segment and are expected to generate incremental revenue starting next financial year,’‘ he added.
The company would remain focused on driving long-term value creation through strategic partnerships, innovation, and continued investments in new products and technologies, according to Sadu.
Shyamakant Giri, the new Chief Executive Officer, said the focus would be on enhancing operational excellence in our base business, ensuring Cenexi’s successful turnaround, identifying and pursuing new growth opportunities.
Post Comment